Rifaximin vs Low-FODMAP Diet in IBS: Non-Responder Subtype

Rifaximin vs Low-FODMAP Diet in IBS: Microbiome Predictors of Rifaximin Response

Rifaximin vs Low-FODMAP Diet in IBS: Fermentation Capacity & FODMAP Response

Rifaximin vs Low-FODMAP Diet in IBS: Changes in Microbial Diversity

Rifaximin vs Low-FODMAP Diet in IBS: Breath Testing

Rifaximin vs Low-FODMAP Diet in IBS: Primary Endpoints

Rifaximin vs Low-FODMAP Diet in IBS: Study Design

Rifaximin vs Low-FODMAP Diet in IBS: Study Objective

Rifaximin vs Low-FODMAP Diet in IBS: Overview of Trial

IBS Biomarkers Review Article: Key Takeaway

IBS Biomarkers Review Article: Leaky Gut

IBS Biomarkers Review Article: Post Infectious IBS

IBS Biomarkers Review Article: Breath Testing

IBS Biomarkers Review Article: Sucrase Isomaltase Deficiency

IBS Biomarkers Review Article: Mechanism Changes Management

IBS Biomarkers Review Article: Mast Cell Activation Subgroup

IBS Biomarkers Review Article: Phenotypes

IBS Biomarkers Review Article: Psychological Burden

IBS Biomarkers Review Article: Overview

Associations Between Physical Activity and IBS: Clinical Takeaway

Associations Between Physical Activity and IBS: Limitations

Associations Between Physical Activity and IBS: Improvement Mechanisms

Associations Between Physical Activity and IBS: Maximum Heart Rate

Associations Between Physical Activity and IBS: Intensity Matters

Associations Between Physical Activity and IBS: Sedentary Minutes

Associations Between Physical Activity and IBS: Daily Steps

Associations Between Physical Activity and IBS: Participant Characteristics

Associations Between Physical Activity and IBS: Fitbit Accuracy

Associations Between Physical Activity and IBS: Overview

Discussing UC & Crohn's Disease: Dr. Kerbage

Discussing UC & Crohn's Disease: Dr. Kerbage

The Safety of Pharmacotherapy for IBS: Limitations

The Safety of Pharmacotherapy for IBS: Key Takeaways

The Safety of Pharmacotherapy for IBS: Individualizing Therapy

The Safety of Pharmacotherapy for IBS: Symptom Flip

The Safety of Pharmacotherapy for IBS: Tricyclic Antidepressants

The Safety of Pharmacotherapy for IBS: IBS-D Results

The Safety of Pharmacotherapy for IBS: IBS-C Results

The Safety of Pharmacotherapy for IBS: Primary Results

The Safety of Pharmacotherapy for IBS: NNH

The Safety of Pharmacotherapy for IBS: Overview

Carbohydrate Intolerance Study: Clinical Implications

Phase 3 BREAKWATER Study: Clinical Implications

Carbohydrate Intolerance Study: Proposed Mechanisms

Carbohydrate Intolerance Study: Predictors of Intolerance

Phase 3 BREAKWATER Study: Safety Profile

Phase 3 BREAKWATER Study: Subgroup Analysis

Carbohydrate Intolerance Study: Fructose Intolerance Symptom Patterns

Phase 3 BREAKWATER Study: Overall Survival

Phase 3 BREAKWATER Study: Duration of Response

Carbohydrate Intolerance Study: Lactose Intolerance Symptom Patterns

Phase 3 BREAKWATER Study: Objective Response Rate

Carbohydrate Intolerance Study: Prevalence of Intolerance

Phase 3 BREAKWATER Study: Population Characteristics

Carbohydrate Intolerance Study: Patient Population

Phase 3 BREAKWATER Study: Trial Design & Endpoints

Carbohydrate Intolerance Study: Design & Methods

Phase 3 BREAKWATER Study: Mechanistic Rationale for Combination Therapy

Carbohydrate Intolerance Study: Distinguishing Malabsorption, Maldigestion, & Intolerance

Carbohydrate Intolerance Study: Overview